Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
News for Tenax Therapeutics, Inc. (TENX) centers on its progress as a Phase 3, development-stage pharmaceutical company focused on cardiopulmonary therapies. The company’s updates highlight the clinical and regulatory path of levosimendan, which it is developing for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a form of pulmonary hypertension for which Tenax states no product has been approved.
Investors following TENX news can expect regular coverage of clinical trial milestones, including enrollment updates, design details, and key analyses from the Phase 3 LEVEL and LEVEL‑2 studies of TNX‑103 (oral levosimendan) in PH-HFpEF. Press releases have described the blinded sample size re-estimation in LEVEL, the initiation of the global LEVEL‑2 study, and the company’s plans for an open-label extension study to provide continued access to TNX‑103 for trial participants.
Tenax news also includes intellectual property developments, such as the European Patent Office’s Intention to Grant a patent covering levosimendan and its active metabolites in PH-HFpEF, and Canadian patent progress for multiple levosimendan formulations and combinations with cardiovascular drugs. These items provide context on the company’s efforts to build long-term protection around its lead asset.
In addition, TENX news features financial results and corporate updates, reported through quarterly earnings press releases, as well as participation in healthcare and investor conferences and virtual KOL events focused on PH-HFpEF and levosimendan. For readers tracking the evolution of Tenax’s late-stage cardiopulmonary program, this news feed offers a consolidated view of trial progress, IP status, and corporate communications. Bookmark this page to follow ongoing disclosures related to TENX and its PH-HFpEF development strategy.
Tenax Therapeutics, Inc. (Nasdaq: TENX) reported its Q3 2020 financial results, revealing a net loss of $2.2 million, or $0.18 per share, stable compared to the previous year. R&D expenses increased slightly to $1.0 million, while G&A expenses decreased to $1.2 million. Cash reserves stood at $8.7 million, expected to fund operations through Q3 2021. The company is advancing its Phase 3 clinical development of levosimendan for pulmonary hypertension and heart failure, and an upcoming R&D webinar is set for November 18, 2020, to discuss recent trial data and updates.
Tenax Therapeutics (Nasdaq: TENX) announced data from the 24-hour open-label portion of the HELP Study, focusing on levosimendan for patients with pulmonary hypertension and heart failure. The study revealed that 36 out of 44 patients, about 85%, responded positively to a 24-hour infusion of levosimendan, showing a significant reduction in pulmonary capillary wedge pressure. These results will be presented at the AHA Scientific Sessions 2020, demonstrating support for the upcoming double-blind phase of the trial.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a virtual R&D webinar for analysts and investors on November 18, 2020, at 4:30 p.m. EST. The webinar will provide updates on levosimendan and its Phase 2 trial targeting pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Esteemed experts including Dr. Stuart Rich and Dr. Daniel Burkhoff will present findings. The trial showed significant improvements in hemodynamic measures and 6-minute walk distances. Archived recordings will be accessible on Tenax's website for 30 days.
Tenax Therapeutics (Nasdaq: TENX) has amended its licensing agreement with Orion Corporation to develop an oral formulation of levosimendan for Type 2 pulmonary hypertension in heart failure patients with preserved ejection fraction. The company plans to utilize this oral formulation in an upcoming Phase 3 trial, which is expected to accelerate patient enrollment compared to the intravenous version. The oral formulation has been previously tested in numerous patients, providing valuable data to support its use. Currently, no products are approved for treating this condition.
Tenax Therapeutics (Nasdaq: TENX) has announced the presentation of detailed results from the Phase 2 HELP Study on levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) at the upcoming HFSA Virtual Annual Meeting from September 30 to October 6. The study demonstrated significant hemodynamic improvements and enhanced exercise capacity. CEO Anthony DiTonno expressed optimism regarding the potential of levosimendan as a groundbreaking treatment, given there are currently no FDA-approved therapies for this condition.